Synagis' Special Status Under Health Care Reform

The new Medicaid rebate rules don’t bite as deeply for drugs approved exclusively for pediatric use. It turns out that AstraZeneca/MedImmune’s Synagis is the only therapy to qualify.

More from Market Access

More from Pink Sheet